At the time of EGFR-TKI treatment initiation in the first-line setting, nine patients (9.4%) had locally advanced and 87 (90.6%) had metastatic NSCLC, while a total of 89 patients had metastatic disease at the time of progression in the first-line setting (Table 2). Here, EGFR is linked to metastatic neoplasm.